Kyverna Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Kyverna Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($36.79M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($42.08M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($42.08M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($44.64M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($44.64M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($44.64M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($34.49M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($28.80M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($28.80M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($26.69M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($26.69M) | May 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($26.69M) | Aug 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.47M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.09M) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($13.09M) | Nov 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($11.14M) | Nov 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.14M) | May 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($11.14M) | Aug 12, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($38.73M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($44.41M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($47.41M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($38.77M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($33.44M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($29.36M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.28M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.30M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.45M) | May 14, 2024 |